Published in J Infect Dis on February 01, 1998
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87
Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav (2012) 1.95
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol (2003) 1.62
Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol (2000) 1.60
Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol (1998) 1.58
Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol (2005) 1.52
Detection of U.S., Lelystad, and European-like porcine reproductive and respiratory syndrome viruses and relative quantitation in boar semen and serum samples by real-time PCR. J Clin Microbiol (2004) 1.50
Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev (2001) 1.49
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. The Division of AIDS Treatment Research Initiative 009 Study Group. J Clin Microbiol (2000) 1.31
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci U S A (2011) 1.30
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol (2002) 1.27
Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One (2011) 1.24
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine (2009) 1.21
Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One (2010) 1.16
HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses (2008) 1.14
Ontogeny and specificities of mucosal and blood human immunodeficiency virus type 1-specific CD8(+) cytotoxic T lymphocytes. J Virol (2003) 1.14
Comparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract. Division of AIDS Treatment Research Initiative 009 Study Team. J Clin Microbiol (2000) 1.14
Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol (2009) 1.11
Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One (2009) 1.11
Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One (2008) 1.07
Viral determinants of HIV-1 macrophage tropism. Viruses (2011) 1.03
The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy. Sex Transm Infect (2005) 1.03
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS (2006) 1.01
HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl (2009) 1.01
Changes in plasma viral load and penile viral shedding after circumcision among HIV-positive men in Kisumu, Kenya. J Acquir Immune Defic Syndr (2013) 0.99
Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma. J Clin Microbiol (2000) 0.98
Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.97
The repertoire of human efforts to avoid sexually transmissible diseases: past and present. Part 1: Strategies used before or instead of sex. Sex Transm Infect (2000) 0.92
A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.91
Use of assisted reproductive technology to reduce the risk of transmission of HIV in discordant couples wishing to have their own children where the male partner is seropositive with an undetectable viral load. J Med Ethics (2003) 0.90
Efficient methodologies for sensitive HIV-1 RNA quantitation from plasma and vaginal secretions. J Clin Virol (2009) 0.90
The male genital tract is not a pharmacological sanctuary from efavirenz. Clin Pharmacol Ther (2011) 0.89
Evaluation of cervical mucosa in transmission bottleneck during acute HIV-1 infection using a cervical tissue-based organ culture. PLoS One (2012) 0.89
Fathers and HIV: considerations for families. J Int AIDS Soc (2010) 0.88
Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection. Cell Mol Immunol (2014) 0.88
Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS (2011) 0.88
The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective. Infect Dis Rep (2013) 0.86
Viral RNA levels and env variants in semen and tissues of mature male rhesus macaques infected with SIV by penile inoculation. PLoS One (2013) 0.85
Semen CD4+ T cells and macrophages are productively infected at all stages of SIV infection in macaques. PLoS Pathog (2013) 0.84
Gynecologic issues in the HIV-infected woman. Infect Dis Clin North Am (2008) 0.83
Genetic characterization of HIV-1 from semen and blood from clade C-infected subjects from India and effect of therapy in these body compartments. Virology (2010) 0.83
Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy. J Virol (2015) 0.83
Molecular epidemiology of feline immunodeficiency virus in the domestic cat (Felis catus). Vet Immunol Immunopathol (2009) 0.83
The semen microbiome and its relationship with local immunology and viral load in HIV infection. PLoS Pathog (2014) 0.82
Post-prostatic massage fluid/urine as an alternative to semen for studying male genitourinary HIV-1 shedding. Sex Transm Infect (2011) 0.82
Multicenter quality control for the detection of hepatitis C virus RNA in seminal plasma specimens. J Clin Microbiol (2003) 0.81
HIV-1 vaginal transmission: cell-free or cell-associated virus? Am J Reprod Immunol (2014) 0.81
Human immunodeficiency virus type-1 episomal cDNA in semen. AIDS Res Ther (2005) 0.80
Oral and vaginal epithelial cell lines bind and transfer cell-free infectious HIV-1 to permissive cells but are not productively infected. PLoS One (2014) 0.80
Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr (2009) 0.80
Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma. Antimicrob Agents Chemother (2002) 0.79
Semen as the Way Forward to Understand HIV-1 Transmission. J Infect Dis (2016) 0.79
Bayesian semiparametric mixture Tobit models with left censoring, skewness, and covariate measurement errors. Stat Med (2013) 0.78
HIV variability in the liver and evidence of possible compartmentalization. AIDS Res Hum Retroviruses (2011) 0.77
Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response. Adv Virol (2012) 0.76
Genotypic and phenotypic heterogeneity in the U3R region of HIV type 1 subtype C. AIDS Res Hum Retroviruses (2013) 0.75
Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. Sex Transm Infect (1999) 0.75
Bayesian inference for a nonlinear mixed-effects Tobit model with multivariate skew-t distributions: application to AIDS studies. Int J Biostat (2012) 0.75
Novel methodology for antiretroviral quantitation in the female genital tract. HIV Clin Trials (2009) 0.75
Elevated urinary leukocyte esterase as a potential surrogate marker for HIV sexual transmission risks in men receiving antiretroviral therapy. Int J STD AIDS (2014) 0.75
The HIV-1 transmission bottleneck. Retrovirology (2017) 0.75
Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men. Open Forum Infect Dis (2017) 0.75
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell (1987) 14.62
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol (1985) 6.94
Fingerprinting Candida albicans. J Immunol Methods (1986) 6.90
Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature (1987) 6.76
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Management of urinary tract infections in adults. N Engl J Med (1993) 6.01
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol (1987) 5.67
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
NIH consensus definition and classification of prostatitis. JAMA (1999) 5.35
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
Customized growth curves for identification of large-for-gestational age neonates in pre-eclamptic women. Ultrasound Obstet Gynecol (2014) 4.86
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med (1996) 4.69
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med (2001) 4.26
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol (1981) 4.10
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med (2001) 3.92
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med (1988) 3.71
Enzyme-linked immunosorbent assay for Campylobacter pyloridis: correlation with presence of C. pyloridis in the gastric mucosa. J Infect Dis (1987) 3.69
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med (1993) 3.51
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. Genes Dev (1991) 3.33
Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med (1980) 3.33
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med (1981) 3.32
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Treatment of intracranial aneurysms by functional reconstruction of the parent artery: the Budapest experience with the pipeline embolization device. AJNR Am J Neuroradiol (2010) 3.08
Effects of electronic fetal-heart-rate monitoring, as compared with periodic auscultation, on the neurologic development of premature infants. N Engl J Med (1990) 3.04
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Clinical manifestations of vaginal trichomoniasis. JAMA (1989) 2.97
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med (2001) 2.83
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Urologic aspects of trichomoniasis. Invest Urol (1981) 2.78
Sexual mixing patterns of patients attending sexually transmitted diseases clinics. Sex Transm Dis (1996) 2.76
Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) (1985) 2.74
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med (1987) 2.74
Sexually transmitted diseases in victims of rape. N Engl J Med (1990) 2.74
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis (2000) 2.64
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med (1994) 2.62
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis (1983) 2.60
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Prematurity and perinatal mortality in pregnancies complicated by maternal Chlamydia trachomatis infections. JAMA (1982) 2.55
Chronic fatigue. A prospective clinical and virologic study. JAMA (1990) 2.54
Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health (1999) 2.54
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50